BRAINSTORM CELL THERAPEUTICS's ticker is BCLI and the CUSIP is 10501E201. A total of 45 filers reported holding BRAINSTORM CELL THERAPEUTICS in Q3 2022. The put-call ratio across all filers is 0.11 and the average weighting 0.0%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $27,586 | -91.9% | 137,860 | -16.2% | 0.00% | – |
Q2 2023 | $339,082 | -37.6% | 164,603 | -0.1% | 0.00% | – |
Q1 2023 | $543,520 | +55.8% | 164,703 | -22.6% | 0.00% | – |
Q4 2022 | $348,833 | -67.8% | 212,703 | -13.1% | 0.00% | -100.0% |
Q3 2022 | $1,082,000 | +109.3% | 244,803 | +30.6% | 0.00% | 0.0% |
Q2 2022 | $517,000 | -19.2% | 187,403 | -1.6% | 0.00% | 0.0% |
Q1 2022 | $640,000 | -15.6% | 190,403 | +0.5% | 0.00% | 0.0% |
Q4 2021 | $758,000 | +14.8% | 189,503 | -11.4% | 0.00% | 0.0% |
Q3 2021 | $660,000 | -13.0% | 213,768 | +7.0% | 0.00% | 0.0% |
Q2 2021 | $759,000 | +0.9% | 199,743 | -9.5% | 0.00% | 0.0% |
Q1 2021 | $752,000 | -52.1% | 220,678 | -36.4% | 0.00% | -50.0% |
Q4 2020 | $1,570,000 | -67.9% | 347,006 | +20.2% | 0.00% | -66.7% |
Q3 2020 | $4,884,000 | +71.4% | 288,675 | +13.6% | 0.01% | +50.0% |
Q2 2020 | $2,849,000 | +205.7% | 254,175 | +26.5% | 0.00% | +300.0% |
Q1 2020 | $932,000 | +79.2% | 200,950 | +65.3% | 0.00% | 0.0% |
Q4 2019 | $520,000 | +53.8% | 121,600 | +40.3% | 0.00% | – |
Q3 2019 | $338,000 | – | 86,700 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
SABBY MANAGEMENT, LLC | 242,850 | $923,000 | 0.13% |
ABNER HERRMAN & BROCK LLC | 241,500 | $918,000 | 0.13% |
Weaver Consulting Group | 48,881 | $186,000 | 0.10% |
Tibra Equities Europe Ltd | 87,000 | $331,000 | 0.10% |
Ikarian Capital, LLC | 293,200 | $1,115,000 | 0.09% |
GSA CAPITAL PARTNERS LLP | 60,238 | $229,000 | 0.03% |
Ergoteles LLC | 124,329 | $472,000 | 0.01% |
CFO4Life Group, LLC | 12,003 | $46,000 | 0.01% |
HighPoint Advisor Group LLC | 17,033 | $65,000 | 0.01% |
BOOTHBAY FUND MANAGEMENT, LLC | 32,836 | $125,000 | 0.00% |